Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M9RE
|
||||
| Former ID |
DIB009950
|
||||
| Drug Name |
ARI-809
|
||||
| Synonyms |
ARI-809; Aldose reductase inhibitors (diabetes); CP-744809; Aldose reductase inhibitors (diabetes), Pfizer
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Preclinical | [1] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C13H9ClN2O4S
|
||||
| Canonical SMILES |
S(=O)(=O)(c1c(c2c(o1)ccc(c2)Cl)C)c1n[nH]c(=O)cc1
|
||||
| CAS Number |
CAS 111477-47-5
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Aldose reductase | Target Info | Inhibitor | [2] | |
| BioCyc Pathway | Methylglyoxal degradation III | ||||
| Acetone degradation I (to methylglyoxal) | |||||
| KEGG Pathway | Pentose and glucuronate interconversions | ||||
| Fructose and mannose metabolism | |||||
| Galactose metabolism | |||||
| Glycerolipid metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Fructose and Mannose Degradation | ||||
| Pyruvate Metabolism | |||||
| Pterine Biosynthesis | |||||
| Glycerolipid Metabolism | |||||
| Galactose Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Polyol Pathway | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032059) | ||||
| REF 2 | A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006 Oct;55(10):2757-62. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.